23:50 , Aug 8, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Non-small cell lung cancer (NSCLC)...
22:25 , Apr 13, 2018 |  BioCentury  |  Emerging Company Profile

Reversing Neuropathy

Regenacy Pharmaceuticals LLC is developing the selective histone deacetylase 6 inhibitor ricolinostat as the first disease-modifying therapy for chemotherapy-induced peripheral neuropathy and diabetic neuropathy. Regenacy was spun out of Acetylon Pharmaceuticals Inc. during its 2016...
16:50 , Feb 13, 2018 |  BC Innovations  |  Distillery Therapeutics

Cardiovascular

INDICATION: Heart failure Patient sample, rat and mouse studies suggest inhibiting HDAC2 could help treat diastolic dysfunction. In postmortem myofibrils from heart failure patients, diastolic relaxation time was longer than in matched samples from unaffected...
19:58 , Sep 21, 2017 |  BC Innovations  |  Tools & Techniques

On your marks

With less fanfare than the first two waves, a quiet rise in activity is driving a revival of interest in epigenetics, despite little progress in solving the fundamental challenges that have dogged the field from...
18:58 , Sep 20, 2017 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Colorectal cancer...
18:41 , Aug 9, 2017 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Cervical cancer; breast cancer Patient sample, cell culture and mouse studies suggest inhibiting HDAC1 alone or in combination with T cell therapies could help treat NANOG -positive cervical and breast cancers. In cervical cancer...
19:21 , Jul 31, 2017 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Alzheimer's disease (AD) Mouse studies suggest inhibiting the FOSB / HDAC1 axis could help treat AD. In dentate gyrus tissue samples from a mouse model of AD, levels of a truncated FOSB isoform were...
22:05 , Dec 9, 2016 |  BC Week In Review  |  Company News

Acetylon, Celgene deal

Acetylon said Celgene will acquire it for undisclosed terms. Prior to the deal's completion, Acetylon will spin out some histone deacetylase (HDAC) assets into newco Regenacy Pharmaceuticals LLC (Boston, Mass.). Celgene will gain rights to...
00:07 , Dec 3, 2016 |  BC Extra  |  Company News

Celgene acquiring Acetylon after spinout of newco

Acetylon Pharmaceuticals Inc. (Boston, Mass.) said Celgene Corp. (NASDAQ:CELG) will acquire it for undisclosed terms. Prior to the deal's completion, Acetylon will spin out some histone deacetylase (HDAC) assets into newco Regenacy Pharmaceuticals LLC (Boston,...
07:00 , Oct 20, 2016 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Alzheimer’s disease (AD)...